Russell Karp

1.8k total citations
16 papers, 711 citations indexed

About

Russell Karp is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Russell Karp has authored 16 papers receiving a total of 711 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Oncology and 3 papers in Organic Chemistry. Recurrent topics in Russell Karp's work include Peptidase Inhibition and Analysis (4 papers), Click Chemistry and Applications (2 papers) and Synthesis and biological activity (2 papers). Russell Karp is often cited by papers focused on Peptidase Inhibition and Analysis (4 papers), Click Chemistry and Applications (2 papers) and Synthesis and biological activity (2 papers). Russell Karp collaborates with scholars based in United States, Japan and Switzerland. Russell Karp's co-authors include William Westlin, Matthew Labenski, Russell C. Petter, Mariana Nacht, Juswinder Singh, Prasoon Chaturvedi, Zhendong Zhu, Michael P. Sheets, Hormoz Mazdiyasni and Thia St Martin and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Russell Karp

16 papers receiving 694 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Russell Karp United States 11 374 210 196 174 105 16 711
Hisako Sakiyama Japan 18 496 1.3× 329 1.6× 145 0.7× 70 0.4× 49 0.5× 42 937
Zahide Özer United States 14 265 0.7× 196 0.9× 135 0.7× 101 0.6× 59 0.6× 23 583
I R Kirsch United States 9 463 1.2× 209 1.0× 103 0.5× 77 0.4× 63 0.6× 14 687
Weiming Duan China 16 406 1.1× 146 0.7× 328 1.7× 93 0.5× 52 0.5× 39 819
Sonali Joshi United States 15 465 1.2× 275 1.3× 272 1.4× 53 0.3× 51 0.5× 29 801
L. Mengle-Gaw United Kingdom 16 401 1.1× 521 2.5× 137 0.7× 126 0.7× 92 0.9× 20 1.1k
Markus Duechler Poland 17 640 1.7× 187 0.9× 178 0.9× 156 0.9× 88 0.8× 29 981
Astrid Clarke United States 11 715 1.9× 234 1.1× 171 0.9× 58 0.3× 55 0.5× 27 1000
Mark L. Sandberg United States 13 290 0.8× 252 1.2× 414 2.1× 51 0.3× 153 1.5× 19 815
Bart Steiner United States 10 518 1.4× 311 1.5× 203 1.0× 480 2.8× 322 3.1× 17 1.0k

Countries citing papers authored by Russell Karp

Since Specialization
Citations

This map shows the geographic impact of Russell Karp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Russell Karp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Russell Karp more than expected).

Fields of papers citing papers by Russell Karp

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Russell Karp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Russell Karp. The network helps show where Russell Karp may publish in the future.

Co-authorship network of co-authors of Russell Karp

This figure shows the co-authorship network connecting the top 25 collaborators of Russell Karp. A scholar is included among the top collaborators of Russell Karp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Russell Karp. Russell Karp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Hewitt, Susannah L., Ailin Bai, D. R. Shackleton Bailey, et al.. (2019). Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs. Science Translational Medicine. 11(477). 223 indexed citations
2.
Evans, Erica N, Richland Tester, Russell Karp, et al.. (2013). Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans. Journal of Pharmacology and Experimental Therapeutics. 346(2). 219–228. 171 indexed citations
3.
Nacht, Mariana, Lixin Qiao, Michael P. Sheets, et al.. (2013). Discovery of a Potent and Isoform-Selective Targeted Covalent Inhibitor of the Lipid Kinase PI3Kα. Journal of Medicinal Chemistry. 56(3). 712–721. 73 indexed citations
4.
Walter, Annette O., Henry J. Haringsma, Kevin Lin, et al.. (2012). Abstract 1791: CO-1686, a novel mutant-selective EGFR inhibitor, overcomes T790M mediated resistance in Non-Small Cell Lung Cancer (NSCLC). Cancer Research. 72(8_Supplement). 1791–1791. 3 indexed citations
5.
Walter, Annette O., Henry J. Haringsma, Kevin Lin, et al.. (2011). Abstract C189: CO-1686, an orally available, mutant-selective inhibitor of the epidermal growth factor receptor (EGFR), causes tumor shrinkage in non-small cell lung cancer (NSCLC) with T790M mutations.. Molecular Cancer Therapeutics. 10(11_Supplement). C189–C189. 11 indexed citations
6.
Evans, Erica N, Sabine Ponader, Russell Karp, et al.. (2011). 2.23 Covalent Inhibition of Btk with Clinical Development Compound AVL-292 Disrupts Signaling That Maintains the Microenvironment Necessary for Chronic Lymphocytic Leukemia Growth. Clinical Lymphoma Myeloma & Leukemia. 11. S173–S174. 10 indexed citations
7.
Hagel, Margit, Deqiang Niu, Thia St Martin, et al.. (2010). Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine. Nature Chemical Biology. 7(1). 22–24. 77 indexed citations
8.
Meetze, Kristan, Kelly Connolly, Hamid Tissire, et al.. (2009). Abstract #1246: Preclinical efficacy and pharmacodynamics of SCH 900105 (AV-299), an anti-HGF antibody. Cancer Research. 69. 1246–1246. 3 indexed citations
9.
Lazarus, Douglas, Matthew Labenski, James Wakefield, et al.. (2008). An inhibitor of methionine aminopeptidase type-2, PPI-2458, ameliorates the pathophysiological disease processes of rheumatoid arthritis. Inflammation Research. 57(1). 18–27. 11 indexed citations
10.
Hannig, Gerhard, et al.. (2007). Suppression of inflammation and structural damage in experimental arthritis through molecular targeted therapy with PPI‐2458. Arthritis & Rheumatism. 56(3). 850–860. 20 indexed citations
11.
Hannig, Gerhard, Douglas Lazarus, Sylvie G. Bernier, et al.. (2006). Inhibition of melanoma tumor growth by a pharmacological inhibitor of MetAP-2, PPI-2458. International Journal of Oncology. 28(4). 955–63. 14 indexed citations
12.
Karp, Russell, Jennifer Hoyt, Matthew Labenski, et al.. (2006). A Novel Methionine Aminopeptidase-2 Inhibitor, PPI-2458, Inhibits Non–Hodgkin's Lymphoma Cell Proliferation In vitro and In vivo. Clinical Cancer Research. 12(8). 2583–2590. 12 indexed citations
13.
Bao, Bagna, Narender Kumar, Russell Karp, H.A. Garverick, & K. Sundaram. (2000). Estrogen Receptor-β Expression in Relation to the Expression of Luteinizing Hormone Receptor and Cytochrome P450 Enzymes in Rat Ovarian Follicles1. Biology of Reproduction. 63(6). 1747–1755. 52 indexed citations
14.
Bandivdekar, A. H., Russell Karp, K. Sundaram, & Narender Kumar. (2000). The Antigonadotropic Action of Testosterone but not 7α‐Methyl‐19‐Nortestosterone Is Attenuated Through the 5α‐Reductase Pathway in the Castrated Male Rat Pituitary Gland. Journal of Andrology. 21(2). 268–275. 7 indexed citations
15.
Warren, Kenneth S., Russell Karp, Ronald P. Pelley, & A. A. F. Mahmoud. (1976). The Eosinophil Stimulation Promoter Test in Murine and Human Trichinella spiralis Infection. The Journal of Infectious Diseases. 134(3). 277–280. 15 indexed citations
16.
Pelley, Ronald P., Russell Karp, A. A. F. Mahmoud, & K. S. Warren. (1976). Antigen Dose Response and Specificity of Production of the Lymphokine Eosinophil Stimulation Promoter. The Journal of Infectious Diseases. 134(3). 230–237. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hisako Sakiyama Breakdown of academic impact, for papers by Zahide Özer Breakdown of academic impact, for papers by I R Kirsch Breakdown of academic impact, for papers by Weiming Duan Breakdown of academic impact, for papers by Sonali Joshi Breakdown of academic impact, for papers by L. Mengle-Gaw Breakdown of academic impact, for papers by Markus Duechler Breakdown of academic impact, for papers by Astrid Clarke Breakdown of academic impact, for papers by Mark L. Sandberg Breakdown of academic impact, for papers by Bart Steiner
Rankless by CCL
2026